Jinglin Zhong

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)

Eric L. Simpson, Seth Forman, Jonathan I. Silverberg et al. · Journal of the American Academy of Dermatology · 2021 · 135 citations

Life Sciences, Dermatology, Pharmacology +11

Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis

Mark C. Genovese, Josef S Smolen, Tsutomu Takeuchi et al. · The Lancet Rheumatology · 2020 · 81 citations

Medicine, Internal Medicine, Pharmacology +14

Statistical Issues of QT Prolongation Assessment Based on Linear Concentration Modeling

Yi Tsong, Meiyu Shen, Jinglin Zhong et al. · Journal of Biopharmaceutical Statistics · 2008 · 43 citations

Medicine, Cardiology, Pharmacology +13

THU0078 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS

Mark C. Genovese, Josef S Smolen, Tsutomu Takeuchi et al. · Annals of the Rheumatic Diseases · 2019 · 28 citations · Full text

Medicine, Internal Medicine, Pharmacology +15

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics

Joel M. Kremer, Michael Schiff, David Muram et al. · RMD Open · 2018 · 21 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14